TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Titan Pharmaceuticals Reborn: What Lies Ahead? VFC submits: Titan Pharmaceuticals (TTNP.OB) commenced trading on the OTC Bulletin Board on Wednesday under the symbol TTNP.OB, after the Financial Industry Regulatory Authority [FINRA] approved the move. Titan's first day on the new board was uneventful as the share price traded sideways throughout the day as the move was largely expected.The OTCBB is a step up for the suddenly re-born Titan Pharmaceuticals, but the more significant news may have been the note in Wednesday's press release regarding the Probuphine patent.Complete Story » seekingalpha.com |
Jazz: Your FDA Panel Primer Rockford Coscia submits:Jazz Pharmaceuticals (JAZZ) is a small biotech firm specializing in treatments for neurology and psychiatry patients. Jazz has two products currently being marketed in the U.S.: Xyrem for the treatment of narcolepsy, and Luvox CR for the treatment of social anxiety disorder and obsessive compulsive disorder. Currently, a new drug application is under review for Jazz's fibromyalgia therapy currently referred to as JZP-6. As part of the evaluation process, the FDA has scheduled a panel, in which it consults experts for potential concerns, for August 20. FDA panels usually cause significant price swings in the stock in the company under evaluation -- so much so that trading is halted for the entire day that the panel takes place. Due to the potentially huge price swing in Jazz's stock, I wanted to address what I thought was especially important for investors (and speculators!) to know heading into this event.Complete Story » seekingalpha.com |
Trident & Smiles Across America - Video More Than One Million Sealants Delivered to Date but Survey Reveals Parents Still Underestimate the Impact of Tooth Decay feedproxy.google.com |
Geron: Buyer Beware In recent days, shares of biopharma company Geron (GERN) have gone viral, up over 20% in a week. News of a clinical trial for an embryonic stem cell therapy aimed at spinal cord injuries has captured the imagination of investors. History should give them pause. I've followed Geron off and on since the company went public. Hoover's reports that the IPO took place on July 31, 1996 at a price of $8 a share. 2 million shares were offered, with a total of 9.7 million shares outstanding after the IPO was completed. The result: a company with an $80 million market value and a pocket full of cash.Complete Story » seekingalpha.com |
Insight Imaging Completes Acquisition of Virginia Imaging Center [Business Wire] - InSight Health Services Holdings Corp. today announced that it has completed the acquisition of a multi-modality imaging center in Roanoke, VA. The acquisition expands Insight Imaging’s presence in Virginia to four locations. us.rd.yahoo.com |